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1. INTRODUCTION
            Snake bites contribute to health problem in India and continue to be a 
major medical concern. India alone contributes to 81,000 envenomations and 
11,000  deaths  annually.  It  appears  that  every  10  seconds  one  individual  is 
envenomed  and  one  among  four  dies  due  to  snake  bite.  Snake  bite  is  an 
occupational  disease  of  farmers  (rice),  plantation  workers  (rubber,  coffee), 
herdsmen, hunters, snake handlers, fishermen and fish farmers.
              In Tamil Nadu the total number of snake bite cases admitted (and 
expired) in the secondary care hospitals alone during 2005 - 2006 and 2006 
-2007 were 19321(85) and 20677(75) respectively. The total number of ASV 
vials used in these hospitals during the respective periods was 94481 and 96800. 
Over all analysis revealed that the snakebites and ASV usage in West, North, 
East,  Central,  South  zone  of  Tamil  Nadu  were  13,  17,  20,  24  and  26% 
respectively.
            Snakebites are observed all over the country with a rural / urban ratio of  
9:1.  They  are  more  common  during  monsoon  and  post  monsoon  seasons. 
Snakebites are seen often among agricultural workers and among those going to 
the forest.  The male /  female ratio among the victims is  approximately 3:2. 
Majority are young and their age is between 25 to 44 years. Most of the bites 
(90 to 95%) are noticed on the extremities (limbs).
          There are more than 3000 species of snakes in the world. For the purpose 
of clinical practice, snakes are classified into poisonous (venomous) and non-
poisonous  (nonvenomous)  snakes.  Poisonous  snakes  common  in  India  are 
classified into these families and they are
            • Elapidae [Cobra group]
            • Viperidae [Viper group]
            • Hydrophidae [Sea snake group]
         
            For many decades, the concept of the “Big 4” snakes of medical 
importance  has  reflected  the  view that  4  species  and responsible  for  Indian 
snakebite mortality. They are the Indian cobra (Naja naja), the Common Krait 
(Bungarus caeruleus), the Russell’s viper (Daboia russelii) and the Saw scaled 
viper (Echis carinatus). However, recently another species, the Hump-nosed pit 
viper  (Hypnale  hypnale),  has  been  found  to  be  capable  of  causing  lethal 
envenomation,  and  that  this  problem  had  been  concealed  by  systematic 
misidentification of this species as the saw-scaled viper. The concept of the “Big 
4”  snakes  has  failed  to  include  all  currently  known  snakes  of  medical 
significance in India.
Anti snake venom (ASV):
           ASV neutralizes the circulating venom only and no amount of ASV will 
neutralize or combine with venom once the venom is attached or adsorbed to 
the  target  organs. Currently  available  ASV in  India  is  polyvalent  i.e.,  it  is 
effective against all the four common species; Russells Viper (Daboia russelii), 
Common Cobra (Naja naja),  Common Krait  (Bungarus caeruleus)  and Saw 
Scaled Viper (Echis carinatus). Indian ASV is a F(ab)2 product derived from 
horse serum and has a halflife of 26-95 hours. Though it is purified, it still can 
be immunogenic.
             In  India  ASV  is  manufactured  by  Bengal  Chemicals  & 
Pharmaceuticals, Kolkata;  Bharat  Serums, Mumbai;  Biological  Evans, 
Hyderabad;  Central Research Institute,  Kausali;  Haffkins Pharmaceuticals, 
Mumbai;  King Institute of  preventive medicine,  Chennai;  Serum Institute, 
Pune and Vins bio-products, Hyderabad.
           The approximate fatal doses of venom of the poisonous snakes are as 
follows:
        1.Russell’s Viper                    :150mg
        2.Saw scaled Viper                 :80mg
        3.Cobra                                    :120mg
        4.Krait                                      :60mg
              The approximate quantity of venom neutralized by 1ml of polyvalent 
ASV is given below:
        1.Russell’s Viper                    :0.60mg
        2.Saw scaled Viper                 :0.45mg
        3.Cobra                                    :0.60mg
        4.Krait                                      :0.45mg
             ASV can save many of the complications and death due to snake bites if 
given  in  time.  However  superstitions,  lack  of  prompt  medical  access,  late 
reporting to health care system and cost of ASV delays the administration of 
ASV. Some authors have postulated that the renal abnormality correlates well 
with late onset of treatment and that early ASV administration prevents renal 
damage. 
              A detailed clinical study correlating the development of complications 
with timing of ASV administration was needed. Therefore present study was 
undertaken  in  inpatients  admitted  with  snake  bite  in  Govt.  Rajaji  hospital, 
Madurai  to  study the  use  of  ASV as an early intervention and to  study the 
relationship of late administration of ASV due to late arrival of patient to the 
hospital with subsequent development of complications.
2. REVIEW OF THE LITERATURE
2.1 CLASSIFICATION:
         There are two important groups (families) of venomous snakes in South-
East Asia –Elapidae have short permanently erect fangs. This family includes 
the  cobras,  king  cobra,  kraits,  coral  snakes  and  the  sea  snakes.  The  most 
important species, from a medical point of view, include the following: 
Cobras:                      N naja                        Common spectacled Indian cobra
(Genus Naja)              N oxiana                         North Indian or Oxus cobra 
                                   N kaouthia                      Monocellate cobra 
                                   N philippinensis              Philippine cobra
                                   N atra                              Chinese cobra 
Spitting cobras:         N siamensis 
                                    N sumatrana 
                                    N sputatrix 
King cobra:                Ophiophagus hannah 
Kraits:                         B caeruleus                      Common krait 
(Genus Bungarus)        B candidus                       Malayan krait 
                                     B multicinctus                  Chinese krait 
                                     B fasciatus                        Banded krait 
Sea snakes:     Important genera include Enhydrina, Lapemis and Hydrophis
        Figure 2.1 Common types of Snakes in India
      Viperidae have long fangs which are normally folded up against the upper 
jaw but,  when  the  snake  strikes,  are  erected.  There  are  two subgroups,  the 
typical  vipers (Viperinae)  and the pit  vipers (Crotalinae).  The Crotalinae 
have a special sense organ, the pit organ, to detect their warm-blooded prey. 
This is situated between the nostril and the eye.
             Medically important  species  in 
South-East  Asia are:
Typical  vipers: Daboia  russelii  
Russell’s vipers 
                                Echis carinatus                       Saw-scaled or carpet vipers
                                E sochureki 
Pit vipers:              Calloselasma rhodostoma         Malayan pit viper
                                Hypnale hypnale                        Hump-nosed viper 
Green pit vipers or bamboo vipers: (Genus Trimeresurus)
                               T albolabris                            White-lipped green pit viper 
                               T gramineus                                Indian bamboo viper
                               T mucrosquamatus                     Chinese habu 
                               T purpureomaculatus                  Mangrove pit viper 
                               T stejnegeri                                 Chinese bamboo viper
Common KraitCommon Cobra
Russell’s Saw Scaled 
2.2 THE VENOM APPARATUS:
             Venomous snakes of medical importance have a pair of enlarged teeth, 
the fangs, at the front of their upper jaw. These fangs contain a venom channel 
(like a hypodermic needle) or groove, along which venom can be introduced 
deep into the tissues of their natural prey. If a human is bitten, venom is usually 
injected subcutaneously or intramuscularly.
2.3 IDENTIFICATION OF VENOMOUS SNAKES:
            Identification of poisonous snakes is complex (involves counting of  
scales) and not definitive (the identification of pre or post maxillary teeth) and 
of no use to a doctor in a medical situation. What is important therefore is to 
focus on the key aspects of identification that enable the medical professional to 
rapidly identify whether they are dealing with a venomous species, and what 
that species might be.
          The following features can be used to identify the poisonous snakes:
1. Pupil size: The pupil of harmless snakes is round. Poisonous snakes have 
elliptical pupils.
2. Pit:  Poisonous snakes have a pit, heat sensitive organ situated between the 
eye and nostril, which detects warm blooded prey. Harmless snakes do not have 
pits.
Figure 2.2 Venomous Snakes identification
3. Scale arrangements: The underside scales of a venomous snake’s tail go all 
the way across in a single row from anal plate. The very tip of the tail may have 
two scale rows. Nonpoisonous snakes have two rows of scales from the vent to 
the end of the tail.
4. Head shape: Venomous snakes have a triangular or spider-shaped head.
5.  Distinctive sounds: Russell’s  viper  will  produce blowing hiss  sound and 
saw-scaled viper will produce grating rasp sound.
2.4 COMPOSITION OF VENOM:
            Snake venoms contain more than 20 different constituents, mainly 
proteins,  including  enzymes  and  polypeptide  toxins.  The  following  venom 
constituents cause important clinical effects:
(i) Procoagulant enzymes (Viperidae) that stimulate blood clotting but result in 
incoagulable blood. Eventually, and sometimes within 30 minutes of the bite, 
the levels of clotting factors have been so depleted (consumption coagulopathy) 
that the blood will not clot. Russell’s viper venom affects factors V, X, platelets 
and  protein  C  while  saw-scaled  viper  venom  activates  prothrombin  and 
plasminogen.
(ii)  Haemorrhagins  (Zinc  metalloproteinases)  that  damage  the  endothelial 
lining of blood vessel walls causing spontaneous systemic haemorrhage.
(iii)  Cytolytic  or  necrotic  toxins  -  these  digestive  hydrolases  (proteolytic 
enzymes and phospholipases A), polypeptide toxins and other factors increase 
permeability resulting in local swelling. 
(iv) Haemolytic and myolytic phospholipases A2 - these enzymes damage cell 
membranes, endothelium, skeletal muscle, nerve and red blood cells.
(v)Pre-synaptic  neurotoxins  (Krait  and  Russell’s  viper)  β-bungarotoxin, 
crotoxin  and  taipoxin  that  contain  phospholipases  A2  that  damage  nerve 
endings,  initially  releasing  acetylcholine  transmitter,  then  interfering  with 
release.
(vi)  Post-synaptic  neurotoxins  (Elapidae) -  these  polypeptides  such  as  α-
bungarotoxin and cobratoxin compete with acetylcholine for receptors in the 
neuromuscular junction and lead to curare-like paralysis.
2.5 QUANTITY OF VENOM INJECTED AT A BITE:
           This is very variable, depending on the species and size of the snake, the 
mechanical efficiency of the bite, whether one or two fangs penetrated the skin 
and whether  there  were  repeated  strikes.  The snake  may  be  able  to  control 
whether or not venom is injected.  
            About 50% of bites by Malayan pit vipers and Russell’s vipers, 30% of 
bites by cobras and 5-10% of bites by saw-scaled vipers do not result in any 
symptoms or signs of envenoming (Dry bites). Snakes do not exhaust their store 
of venom, even after several strikes, and they are no less venomous after eating 
their  prey.  Although  large  snakes  tend  to  inject  more  venom  than  smaller 
specimens of the same species, the venom of smaller, younger vipers may be 
richer in some dangerous components, such as those affecting haemostasis.
2.6 HOW DO SNAKE BITES HAPPEN?
               In South-East Asia, snake bite is an occupational hazard of rice 
farmers; rubber, coffee and other plantation workers; fishermen and those who 
handle snakes. Most snake bites happen when the snake is trodden on, either in 
the dark or in undergrowth, by someone who is bare-footed or wearing only 
sandals. Some bites occur when the snake (usually a krait) comes in to the home 
at night in search of its prey (other snakes, lizards, frogs, mice) and someone 
sleeping on the floor rolls over onto the snake in their sleep. 
2.7 SYMPTOMS AND SIGNS:
               Some people who are bitten by snakes or suspect or imagine that they 
have been bitten, may develop quite striking symptoms and signs, even when no 
venom has been injected. This results from fear of the consequences of a real 
venomous bite. Anxious people may overbreathe so that they develop pins and 
needles  of  the  extremities,  tetany  of  their  hands  and  feet,  dizziness  and 
vasovagal shock. Forcible insufflation of oils into the respiratory tract may lead 
to aspiration pneumonia, bronchospasm and pneumothorax.
2.7.1  GENERAL  SYMPTOMS  AND  SIGNS  OF  VIPERINE 
ENVENOMATION:
Local effects:
          • Swelling and local pain with or without erythema
          • Tender enlargement of local lymph nodes
          • Bruising and local inflammation
          • Fang marks
Systemic effects:
          • Bleeding from the gingival sulci and other orifices, epistaxis, petechiae, 
purpura and ecchymoses.
          • Renal failure in cases of Russell’s viper and sea snake due to acute 
tubular necrosis secondary to prolonged hypotension, hypovolemia, DIC, direct 
toxic effect of venom on the renal tubule, hemoglobinuria, myoglobinuria and 
hyperkalaemia.
          • Hypotension resulting from hypovolaemia, direct vasodilation and direct 
effect on the myocardium, cardiac arrhythmias and  pulmonary oedema.
          • Muscle pain indicating rhabdomyolysis.
          • Parotid swelling, conjunctival oedema, sub-conjunctival haemorrhage.
          • Endocrine-acute pituitary/adrenal insufficiency.
2.7.2  GENERAL  SYMPTOMS  AND  SIGNS  OF  ELAPID 
ENVENOMATION
Local effects:
           • Swelling and local pain with or without erythema (Cobra).
           • Local necrosis and / or blistering / bullae (Cobra).
Neurotoxic effects:
          • Descending paralysis, initially of muscles innervated by the cranial 
nerves, commencing with ptosis, diplopia, or ophthalmoplegia. There may be 
some involvement of the senses of taste and smell.
          • Problems of vision, breathing and speech.
         • Paralysis of jaw and tongue may lead to upper airway obstruction and 
aspiration of pooled secretions because of the patient’s inability to swallow.
         • Numbness around the lips and mouth, progressing to bulbar paralysis 
and respiratory failure.
         •  Hypoxia due to inadequate ventilation can cause cyanosis,  altered 
sensoriun and coma. 
         • Krait bites often present in early morning with paralysis that can be 
mistaken for a stroke. 
Figure-2.3 Cellulitis and blisters
Figure-2.4 Ptosis in neurotoxicity
2.8 LONG TERM COMPLICATIONS (SEQUELAE) OF SNAKE BITE:
            At the site of the bite, chronic ulceration, infection, osteomyelitis or 
arthritis  may  persist  causing  severe  physical  disability.  Malignant 
transformation may occur in skin ulcers after a number of years. Chronic renal 
failure occurs after bilateral cortical necrosis (Russell’s viper bites) and chronic 
panhypopituitarism or  diabetes  insipidus  after  Russell’s  viper  bites.  Chronic 
neurological  deficit  is  seen  in  the  few  patients  who  survive  intracranial 
haemorrhages (Viperidae).
Table 2.1 Snakes, clinical aspects and therapeutic response:
Features Cobra
s 
Kraits Russell’s 
viper
Saw 
scaled 
viper
Hump 
nosed 
viper
Local Pain /Tissue
Damage
Yes No Yes Yes Yes
Ptosis / Neurological
Signs
Yes Yes Yes No No
Haemostatic
abnormalities
No No Yes Yes Yes
Renal Complications No No Yes No Yes
Response to
Neostigmine
Yes No No No No
Response to ASV Yes Yes Yes Yes No
2.9 INVESTIGATIONS:
(i) 20 Minutes Whole Blood Clotting Test (20WBCT):
             The 20 Minutes Whole Blood Clotting Test (20WBCT) is considered as 
the most reliable test for coagulation. It is significantly superior to the ‘capillary 
tube’ method and is the preferred method of choice in snakebite. If the 20WBCT 
is normal in a suspected case of poisonous snakebites, the test should be carried 
out every 30 minutes from admission for three hours and then hourly after that. 
If incoagulable blood is discovered, the 6 hourly cycle will then be adopted to 
test for the requirement of repeat doses of ASV. This is due to the inability of 
the liver to replace clotting factors under 6 hrs. 
        The test is done as follows:    
       • Place a few mls of freshly sampled venous blood in a small glass vessel
       • Leave undisturbed for 20 minutes at ambient temperature
       • Tip the vessel once
       •  If  the blood is  still  liquid (unclotted)  and runs out,  the patient  has 
hypofibrinogenaemia as a result of venom-induced consumption coagulopathy.
           • Warning! If the vessel used for the test is not made of ordinary glass, or 
if it has been used before and cleaned with detergent, its wall may not stimulate 
clotting of the blood sample in the usual way and test will be invalid.
(ii) Other Useful Tests:
a) Haemoglobin concentration/haematocrit: A transient increase indicates 
haemoconcentration resulting due to increase in capillary permeability, 
blood loss or intravascular haemolysis.
b) Platelet count: This may be decreased in victims of viper bites.
c) White blood cell count: An early neutrophil leucocytosis is present.
d) Blood film: Fragmented red cells (“helmet cell”, schistocytes) are seen 
when there is microangiopathic haemolysis.
e) Plasma/serum may  be  pinkish  or  brownish  if  there  is  gross 
haemoglobinaemia or myoglobinaemia.
f) Biochemical  abnormalities: Aminotransferases  and  muscle  enzymes 
(creatine kinase,  aldolase  etc)  will  be elevated  if  there  is  severe local 
damage or generalised muscle damage. Bilirubin is elevated following 
massive extravasation of blood. Creatinine and urea levels are raised in 
the renal failure. Early hyperkalaemia may be seen following extensive 
rhabdomyolysis. 
g) Arterial blood gases and pH may show evidence of respiratory failure 
and acidaemia (respiratory or metabolic acidosis).
h) Urine  examination: Microscopy  will  confirm  whether  there  are 
erythrocytes  in  the  urine.  Red cell  casts  indicate  glomerular  bleeding. 
Massive proteinuria  is  an  early  sign  of  the  generalised  increase  in 
capillary permeability in Russell’s viper envenoming.
2.10 MANAGEMENT OF SNAKE BITE:
2.10.1First aid: ‘do it “RIGHT”’
R. = Reassure the patient.
(70% of all snakebites are from non-venomous species. Only 50% of bites by 
venomous species actually envenomate the patient)
I = Immobilize in the same way as a fractured limb.
(Use bandages or cloth to hold the splints, not to block the blood supply or
     apply pressure. Do not apply any compression in the form of tight ligatures,
they don’t work and can be dangerous!)
G. H. = Get to Hospital Immediately.
(Traditional remedies have NO PROVEN benefit in treating snakebite).
T= Tell the doctor of any telltale signs and symptoms such as ptosis that 
manifest on the way to hospital.
  
2.10.2 Pressure Immobilization Method (PIM):
             PIM was developed in Australia in 1974 by Sutherland and gained some 
supporters on television. Further work done by Howarth demonstrated that the 
pressure, to be effective, was different in the lower and upper limbs. The upper 
limb pressure was 40-70mm of Mercury; the lower limb was     55-70mm of 
mercury. In addition, pressure bandages should not be used where there is a risk 
of local necrosis that is in 4/5 of the medically significant snakes of India. 
             In short, pressure-immobilization should be used only in cases where 
the offending snake is reliably identified and has a primarily neurotoxic venom, 
the rescuer is skilled in pressure-wrap application, and the victim can be carried 
to medical care—an uncommon combination of conditions. Initial research has 
suggested that a ‘Pressure Pad or Monash Technique’ may have some benefit 
in the first aid treatment of snakebite.
2.10.3 Indications for ASV:
            ASV treatment is recommended if and when a patient with proven or 
suspected snake bite develops one or more of the following signs.
Systemic envenomation:
a) Haemostatic  abnormalities:  spontaneous  systemic  bleeding, 
coagulopathy (20WBCT) or thrombocytopenia
b) Neurotoxic signs: ptosis, external ophthalmoplegia, paralysis, etc 
c) Cardiovascular abnormalities: hypotension, shock, cardiac arrhythmia 
and abnormal ECG
d) Acute renal failure: oliguria/anuria  and rising blood creatinine/ urea 
e) Haemoglobinuria/myoglobinuria: dark  brown  urine,  urine  dipsticks, 
other  evidence  of  intravascular  haemolysis  or  generalised 
rhabdomyolysis 
f) Supporting laboratory evidence of systemic envenomation
Local envenomation:
a) Local swelling involving more than half of the bitten limb (in the absence 
of a tourniquet) and swelling after bites on the digits (toes and especially 
fingers)
b) Rapid  extension  of  swelling  (for  example  beyond  the  wrist  or  ankle 
within a few hours of bites on the hands or feet)
c) Development of an enlarged tender lymph node draining the bitten limb
       ASV treatment should be given as soon as it is indicated. It may reverse 
systemic envenoming even when this has persisted for several days or, in the 
case of haemostatic abnormalities, for two or more weeks. However, when there 
are  signs  of  local  envenoming,  without systemic  envenoming,  ASV will  be 
effective only if it can be given within the first few hours after the bite (WHO 
guidelines).
2.10.4 Precautions before ASV:
            There is no absolute contraindication to ASV. In the absence of any 
prophylactic regimen that has proved effective in clinical trials, the high risk 
patients with strong history of atopic diseases may be pre-treated  empirically 
with  subcutaneous  adrenaline  (0.25mg  of  0.1%),  intravenous  antihistamines 
(both  anti-H1,  such  as  promethazine;  and  anti-  H2,  such  as  ranitidine)  and 
corticosteroid. In asthmatic patients, prophylactic use of an inhaled adrenergic 
β2 agonist such as salbutamol may prevent bronchospasm.
2.10.5 Administration of ASV:
Two methods of administration are recommended:
(1)  Intravenous  “push”  injection: Reconstituted  freeze-dried  antivenom  or 
liquid antivenom is given by slow intravenous injection (not more than          2  
ml/minute). 
(2)  Intravenous  infusion:  Reconstituted  freeze-dried  or  liquid  antivenom is 
diluted in approximately 5-10 ml of isotonic fluid per kg body weight          (ie 
250-500 ml of isotonic saline or 5% dextrose in case of adults) and is infused at 
a constant rate over a period of about one hour.
              Local administration of ASV at the site of the bite is not recommended 
as it is extremely painful, may increase intracompartmental pressure and has not 
been effective. Intramuscular injection of ASV reach blood very slowly. Other 
disadvantages are the pain and haematoma formation. ASV must never be given 
by the intramuscular route if it could be given intravenously.
            Situations in which intramuscular administration might be considered:
(i) At a peripheral first aid station, before a patient with obvious envenomation 
is put in an ambulance for a journey to hospital that may last several hours
(ii) On an expedition exploring a remote area very far from medical care
(iii) When intravenous access has proved impossible
           Under these unusual circumstances, the dose of ASV should be divided 
between a number of sites in the upper anterolateral region of both thighs. A 
maximum  of  5-10  ml  should  be  given  at  each  site  by  deep  intramuscular 
injection followed by massage to aid absorption. 
           ASV should never be injected into the gluteal region (upper outer 
quadrant of the buttock) as absorption is exceptionally slow and unreliable and 
there is always the danger of sciatic nerve damage when the injection is given 
by an inexperienced operator.
2.10.6 Dose of antivenom:
           Snakes inject the same dose of venom into children and adults. Children 
must therefore be given exactly the same dose of ASV as adults. In practice, the 
choice of an initial dose of ASV is usually empirical.  For neurotoxic /  anti 
haemostatic  envenomation,  8  to  10  vials  of  ASV is  recommended  to  be 
administered as initial dose.
Repeat Doses of ASV:
         If on reassessment after 1 - 2hrs the initial dose has been unsuccessful in 
reducing the symptoms / if the symptoms have worsened / if the patient has 
gone into respiratory failure then a further dose should be administered. This 
dose should be the same as the initial dose, and then ASV is discontinued. 20 
vials is the maximum dose of ASV that should be given to a neurotoxically 
envenomed patient. Once a patient in respiratory failure, has received 20 vials 
of ASV and is supported on a ventilator, ASV therapy should be stopped. 
         In the case of anti haemostatic envenomation, the ASV strategy will be 
based around a six hour time period. After the initial ASV, no additional ASV 
will be given until the next clotting test is carried out. This is due to the inability 
of the liver to replace clotting factors within 6 hours. After 6 hours a further 
coagulation test should be performed and a further dose should be administered 
in the event of abnormal test. Clotting tests and repeat doses of ASV should 
continue on a 6 hourly pattern until coagulation is restored. The repeat dose 
should be 5 -10 vials of ASV i.e., half to one full dose of the original amount. 
The  most  logical  approach  is  to  administer  the  same  dose  again,  as  was 
administered initially. 
             The normal guidelines are to administer ASV every 6 hours until  
coagulation has been restored. However, what should the clinician do after say, 
30 vials have been administered and the coagulation abnormality persists?  At 
this point the clinician should consider whether the continued administration of 
ASV is  serving any purpose,  particularly in  the absence of  proven systemic 
bleeding. At this stage the use of Fresh Frozen Plasma (FFP), cryoprecipitate 
(fibrinogen, factor VIII) fresh whole blood, thrombocytes or coagulation factors 
can be considered, if available.
2.10.7 ASV reactions:
           A proportion of patients, usually more than 20%, develop a reaction 
either early (within a few hours) or late (5 days or more) after being given ASV.
A) Early  anaphylactic  reactions: Usually  within 10-180 minutes  of  starting 
ASV, the patient begins to itch and develops urticaria, dry cough, fever, nausea, 
vomiting,  abdominal  colic,  diarrhoea  and  tachycardia.  A minority  of  these 
patients  develop  severe  life-threatening  anaphylaxis:  hypotension, 
bronchospasm and angio-oedema. These reactions are not truly “allergic”. They 
are not IgE-mediated but by complement activation or direct stimulation of mast 
cells or basophils by antivenom protein are more likely mechanisms.
b) Pyrogenic (endotoxin) reactions:  Usually develop 1-2 hours after treatment. 
Symptoms include  shaking chills  (rigors),  fever,  vasodilatation  and a  fall  in 
blood pressure. These reactions are caused by pyrogen contamination during the 
manufacturing process. 
c)  Late  (serum sickness  type)  reactions:  develop  1-12  (mean  7)  days  after 
treatment. Clinical features include fever, nausea, vomiting, diarrhoea, itching, 
recurrent  urticaria,  arthralgia,  myalgia,  lymphadenopathy,  periarticular 
swellings, mononeuritis multiplex, proteinuria with immune complex nephritis 
and rarely encephalopathy.
2.10.8 Treatment for ASV reactions:
(i) Discontinue ASV 
(ii) Administer Inj. Adrenaline 0.5ml of 1:1000 IM, (Adults). 
(If  after  10  to  15  minutes  the  patient’s  condition  has  not  improved  or  is 
worsening,  a second dose of 0.5 ml of Adrenaline IM is given. This can be 
repeated for a third and final occasion but in the vast majority of reactions 2 
doses of Adrenaline will be sufficient).
(iii) Start an adrenaline infusion if the patient remains shocked, (preferably via a 
central venous line), commencing at 0.25 microgram/kg/minute, and titrating as 
required to restore blood pressure. 
(iv)  Antihistamines:  Administer  both H1 receptor blockers Chlorpheniramine 
maleate 10 - 20mg as IV / IM and H2 receptor blockers Ranitidine 1mg/kg
(v)Administer Corticosteroids intravenously: Hydrocortisone 2 - 6mg/kg or
Dexamethasone 0.1 - 0.4mg/kg.
(vi)  Late (serum sickness) reactions usually respond to a 5-day course of oral 
antihistamine (Chlorpheniramine: adults 2 mg six hourly). Patients who fail to 
respond in 24-48 hours should be given a 5-day course of prednisolone (adults 5 
mg six hourly).
2.10.9 Recovery Phase:
          If  an adequate dose of ASV has been administered,  the following 
responses may be seen:    
a) Spontaneous systemic bleeding such as gum bleeding usually stops within 15 
to 30 minutes.
b) Blood coagulability is usually restored in 6 hours (20WBCT).
c)  Post  synaptic  neurotoxic  envenoming  such  as  the  Cobra  may  begin  to 
improve as early as 30 minutes after ASV, but can take several hours.
d)  Presynaptic  neurotoxic  envenoming  such  as  the  Krait  usually  takes  a 
considerable time to improve reflecting the need for the body to generate new 
acetylcholine emitters.
e) Active haemolysis and rhabdomyolysis may cease within a few hours and the 
urine returns to its normal colour during the course of treatment.
f) In patients with shock, blood pressure may increase after 30 minutes while on 
treatment.
2.10.10 Recurrence of systemic envenoming:
             In patients envenomed by vipers, after an initial response to ASV 
(cessation  of  bleeding,  restoration of  blood coagulability),  signs  of  systemic 
envenoming may recur within 24-48 hours.
This is attributable to:
(1) Continuing absorption of venom from the “depot” at the site of the bite
(2) A redistribution of venom from the tissues into the vascular space, as the 
result of ASV treatment.
Criteria for repeating the initial dose of ASV
        a)   Persistence or recurrence of blood incoagulability after 6 hours or  
bleeding after 1-2 hr.
         b) Deteriorating neurotoxic or cardiovascular signs after 1-2 hr.
2.10.11 Treatment of the complications:
(1) Neurotoxic envenomation and respiratory paralysis: 
        Assisted ventilation has proved effective. Acetylcholinesterase inhibitors 
(e.g., edrophonium and neostigmine) may promote neurologic improvement in 
patients bitten by snakes with postsynaptic neurotoxins. 
Anticholinesterase (“Tensilon”/Edrophonium) test:
1. Patients with clear, objective evidence of neurotoxicity after snakebite (e.g., 
ptosis  or  inability  to  maintain  upward  gaze)  should  receive  a  trial  of 
edrophonium (if available) or neostigmine.
a. Pretreat with atropine: 0.6 mg IV (children, 0.02 mg/kg)
b. Follow with: 
Edrophonium: 10 mg IV (children, 0.25 mg/kg) or
Neostigmine: 1.5–2.0 mg IM (children, 0.025–0.08 mg/kg)
2. If objective improvement is evident at 5 min, continue neostigmine at a dose 
of 0.5 mg (children, 0.01 mg/kg) every 30 min as needed, with continued 
administration  of  atropine  by  continuous  infusion  of  0.6  mg  over  8  h 
(children, 0.02 mg/kg over 8 h).
3.  If  edrophonium  chloride  is  not  available,  any  other  anticholinesterases 
(distigmine, pyridostigmine, ambenomium) can be used for this assessment 
but a longer period of observation will be needed (up to one hour).
4. Maintain  vigilance  regarding  aspiration  risk,  and  secure  the  airway  with 
endotracheal intubation as needed.
(2) Hypotension and shock:
             Ideally, hypotension should be treated with plasma expanders (colloids 
or crystalloids) with observation of the central venous pressure (jugular venous 
pressure).  Excessive  volume  replacement  may  cause  pulmonary  oedema.  In 
patients  with  evidence  of  a  generalised  increase  in  capillary  permeability,  a 
selective  vasoconstrictor  such  as  dopamine  may  be  given  by  intravenous 
infusion, preferably into a central vein (starting dose 2.5-5 μg/kg/minute).
             In victims of Russell’s viper bites in South India, acute pituitary and  
adrenal  insufficiency  resulting  from haemorrhagic  infarction  of  the  anterior 
pituitary and adrenals may contribute to shock. Hydrocortisone is effective in 
these cases.
(3) Renal failure:
             Most, but not all, patients with acute renal failure are oliguric, defined  
as a urine output of less than 400 ml/day or less than 20 ml/hour. If the patient is 
hypovolaemic, indicated by supine or postural hypotension, empty neck veins, 
sunken eyeballs, loss of skin turgor and dryness of mucosae, proceed as follows:
(a) Establish intravenous access
(b) Insert a urethral catheter
(c) Determine the central venous pressure. 
(d) Fluid challenge: depending on the initial state of hydration/dehydration, an 
adult patient can be given two litres of isotonic saline over one hour or, until the 
jugular venous pressure has risen to 8-10 cm above the sternal angle.  The fluid 
challenge must be stopped immediately if pulmonary oedema develops. If the 
urine output does not improve, try furosamide challenge.
(f)  Furosamide  challenge: 100  mg  of  furosamide  is  injected  slowly  (4-5 
mg/minute). If this does not induce a urine output of 40 ml/hour, give a second 
dose of furosamide,  200 mg. If urine output does not improve,  try mannitol 
challenge.
(g) Mannitol challenge: 200 ml of 20% mannitol may be infused intravenously 
over 20 minutes but this must not be repeated as there is a danger of inducing 
dangerous fluid and electrolyte imbalance. An improvement in urine output to 
more than 40 ml/hr or more than 1 litre/day is considered satisfactory.
(h)  Conservative management: If the urine output does not improve, despite 
these challenges, no further diuretics should be given and fluid intake should be 
restricted to a total of the previous day’s output plus “insensible losses” (500-
1000 ml/day). If possible, the patient should be referred to a renal unit. 
(i) Biochemical monitoring: Serum potassium, urea, creatinine and, if possible, 
pH, bicarbonate, calcium and phosphate should be monitored frequently.
 (j) Dialysis.
          Prevention  of  renal  damage  in  patients  with  myoglobinuria  or 
haemoglobinuria is by
        • Correcting hypovolaemia and maintain saline diuresis (if possible)
        • Correcting severe acidosis with bicarbonate
        • Giving a single infusion of 20% mannitol (200 ml over 20 minutes)
          In the diuretic phase of renal failure urine output increases. The patient 
may  become polyuric  and  volume  depleted  so  that  salt  and  water  must  be 
carefully  replaced. Hypokalaemia may develop,  in which case a diet  rich in 
potassium (fruit and fruit juices) is recommended.  
Persisting renal dysfunction:
         In India, 20-25% of patients referred to renal units with acute renal failure  
following  Russell’s  viper  bite  suffered  oliguria  for  more  than  4  weeks 
suggesting  the  possibility  of  bilateral  renal  cortical  necrosis.  Patients  with 
patchy cortical necrosis show delayed and partial recovery of renal function but 
those  with diffuse cortical  necrosis  require  regular  maintenance  dialysis  and 
eventual renal transplantation.
(4) Haemostatic disturbances:
               In cases of severe bleeding or imminent urgent surgery, restoration of 
coagulability and platelet  function can be accelerated by giving fresh frozen 
plasma, cryoprecipitate, fresh whole blood or platelet concentrates. Heparin and 
antifibrinolytic agents are not effective.
(5) Bacterial infections:
             Infection at the time of the bite with organisms from the snake’s venom 
and buccal cavity is common. In this case, a prophylactic course of penicillin 
(or  erythromycin  for  penicillin-hypersensitive  patients)  and  a  single  dose  of 
gentamicin,  together with a booster  dose of  tetanus toxoid is  recommended. 
Interference with the wound creates a risk of secondary bacterial infection and 
justifies  the  use  of  broad  spectrum  antibiotics  (eg.  amoxicillin  or  a 
cephalosporin plus a single dose of gentamicin plus metronidazole).
(6) Compartment syndrome:
The clinical features of a compartmental syndrome are
         • Disproportionately severe pain
         • Pain on passive stretching of intra compartmental muscles
         • Hypoaesthesia of areas of skin supplied by underlying nerves
         • Obvious tension and tenderness of the compartment on palpation
Detection of arterial pulses by palpation or doppler ultrasound probes, does not 
exclude intra compartmental  ischaemia.  The most  reliable test  is  to measure 
intra  compartmental  pressure  directly  through  a  cannula  introduced  into  the 
compartment.  Intracompartmental  pressures  exceeding  40  mmHg  (less  in 
children) may carry a risk of ischaemic necrosis. However, fasciotomy should 
not be contemplated until haemostatic abnormalities have been corrected. 
            In one study which was conducted by  Narvencar K.,  JAPI., 2006 
Sep;54:717-9  showed that incidence of complications was directly proportional 
to the duration of venom in the blood prior to neutralization by ASV due to late 
arrival  of  patient  at  hospital.  The  early  institution  of  ASV is  beneficial  in 
preventing complications in the systemic envenomation.
         In another study by  S. R. Vijet et al.,  JIPMER concluded that renal 
abnormality correlated well with the degree of coagulation abnormality when 
left  untreated due to late arrival at the hospital. Early administration of ASV 
prevents renal damage.
3. AIMS AND OBJECTIVES:
              The present study was undertaken to study the relationship between the 
time of anti-snake venom (ASV) administration due to late arrival of patient at 
hospital and subsequent development of complications.
4. MATERIAL AND METHODS:
Study design: Analytical study
Place: Department of Medicine, Govt. Rajaji Hospital, Madurai.
Period: 6 months (July- December 2008) 
Collaborating departments:  Department of Biochemistry
                                              Madurai Medical College
                                              Madurai. 
                                              Department of Nephrology
                                              Madurai Medical College
                                              Madurai. 
Sample size: 164
Selection of the study subjects:  164 patients admitted with snake bite in the 
medical wards, Govt. Rajaji Hospital from July to December 2008 formed the 
study group. 
Inclusion criteria:
1. Local signs of envenomation:
            • Swelling and local pain with or without erythema
            • Tender enlargement of local lymph nodes
            • Local inflammation
            • Local necrosis and / or blistering / bullae 
   
2. Haematological signs of envenomation 
• Haemostatic  abnormalities:  spontaneous  systemic  bleeding, 
coagulopathy (20WBCT) or thrombocytopenia
• Cardiovascular  abnormalities:  hypotension,  shock,  cardiac 
arrhythmia and abnormal ECG
• Acute renal failure:  oliguria/anuria  and rising blood creatinine and 
urea 
• Haemoglobinuria/myoglobinuria: dark brown urine, urine dipsticks, 
other  evidence  of  intravascular  haemolysis  or  generalised 
rhabdomyolysis 
3. Neurological signs of envenomation 
     •   Ptosis, diplopia, dysphagia and dysphonia 
• Muscle paralysis/weakness
• Respiratory distress 
• Confusion
Exclusion criteria:
     1 Persons who did not show any signs of envenomation 
     2. Patients who had received ASV prior to presenting to our institution
Investigations done:
1) 20 minute Whole Blood Clotting Time (20WBCT)
2) Blood sugar, urea and serum creatinine
3) Urine for albumin, sugar and deposits
4) Complete blood count
5) Liver function tests
6) Ultrasonogram (for selected patients)
Complications noted:
a) Acute renal failure (serum creatinine >1.5 mg/dl or oliguria <400ml/day )
b) Disseminated intravascular coagulation or primary fibrinolysis
c) Compartment syndrome
d) Gangrene of the bitten part
e) Cellulitis/necrosis that needed debridement
f) Shock
g) Sepsis
h) Acute respiratory distress syndrome
i) Neurological paralysis requiring ventilatory support
Treatment used:
i. Anti snake venom (ASV)
ii. Antibiotics
iii. Neostigmine and atropine for neurotoxicity
iv. Wound debridement and fasciotomy
v. Hemodialysis for acute renal failure
vi. Artificial ventilation for respiratory failure
vii. Supportive management
Consent: Informed consent was obtained
Ethical committee approval: Obtained
Financial support: Nil
Conflict of interest: Nil
Statistical tool used: The information collected regarding all the selected cases 
were  recorded in  a  Master  Chart.  Data  analysis  was  done  with  the  help  of 
computer using Epidemiological Information Package (EPI 2008).
Using  this  software  range,  frequencies,  percentages,  means,  standard 
deviations, chi square and 'p' values were calculated. Kruskul Wallis chi-square 
test  was  used  to  test  the  significance  of  difference  between  quantitative 
variables and Yate’s test for qualitative variables. A 'p' value less than 0.05 is 
taken to denote significant relationship.
5. RESULTS
In our study, 164 patients were studied. The following results were obtained.
Table-5.1 Age distribution
Age group Total cases
No. Percentage
Upto 20 yrs 25 15.2
21-30 yrs 39 23.8
31-40 yrs 39 23.8
41-50 yrs 34 20.7
>50 yrs 27 16.5
Total 164 100
Range 13-70 yrs
Mean 36.7 yrs
SD 14.2 yrs
        In our study, among the total 164 patients 15.2% of patients (25) were 
below 20 years of age, 23.8% of patients (39) belonged to 21-30 years of age, 
23.8% of patients (39) belonged to 31-40 years of age, 20.7% of patients (34) 
belonged to 41-50 years of age and 16.5% of patients (27) were in the age group 
of above 50 years. Most of the patients were in the age group of 21-50 years.
Figure 5.1 Age Distribution
      Table-5.2 Sex distribution
Sex Cases
No. Percentage
Male 104 63.4
Female 60 36.6
Total 164 100
         
         As seen in table-5.2 in our study, of the total 164 patients 63.4% of  
patients (104) were males and 36.6% of the patients (60) were females. Males 
were more commonly bitten by snakes.
Table-5.3 Place of the snake bite
Bite place Cases
No. Percentage
House 40 24.4
Field 124 75.6
Total 164 100
      Among the 164 patients of our study, as in the table-5.3, 75.6% of the snake  
bites (124) occurred in their working fields and 24.4% of the snake bites (40) 
occurred in their houses. More number of snake bites occurred in the fields.
Figure 5.2 Sex Distribution
Figure 5.3 Place of Snake bite
Table-5.4 Site of the snake bite
Bite site Cases
No. Percentage
Right upper limb 14 8.5
Right lower limb 68 41.6
Left upper limb 22 13.4
Left lower limb 59 35.9
Others 1 0.6
     In our study as in table-5.4, 41.6% of snake bites (68) occurred in right 
lower limb, 35.9% of the bites (59) occurred in left lower limb, 13.4% of the 
bites (22) occurred in left upper limb, 8.5% of the bites (14) occurred in right 
upper limb and one case reported  in the forehead.
Table-5.5 Type of presentation 
Presentation Cases
No. Percentage
Local 149 90.9
Neurological 15 9.1
Total 164 100
Figure 5.4 Site of Snake bite
Figure 5.5 Type of presentation
             In this study, 90.9% of the patients (149) presented to the hospital with 
the  local  manifestations  of  envenomation  and  9.1%  of  the  patients  (15) 
presented with neurotoxic manifestations.
Table-5.6 Clotting time abnormalities
Clotting time Cases
No. Percentage
Normal (<20 min) 53 32.3
Abnormal (>20 min) 111 67.7
Total 164 100
          Among the 164 patients in this study, 67.7% of the patients (111) 
presented with prolonged clotting time and 32.3% of the patients (53) presented 
with normal clotting time.
Figure 5.6 Clotting abnormalities
Table-5.7 Supportive treatment
Supportive treatment Cases
No. Percentage
Blood transfusion 4 2.4
Dialysis 14 8.5
Fasciotomy 4 2.4
Ventilator support 11 6.7
Nil 131 79.9
Total 164 100
           In our study, 8.5% of the patients (14) of the total 164 needed dialysis for  
the treatment of renal failure. 6.7% of the patients (11) needed ventilator support 
for respiratory failure, 2.4% of the patients (4) needed blood transfusion and 
2.4% of the patients needed fasciotomy for the treatment of the compartment 
syndrome.  Among  the  164  patients,  79.9%  of  the  patients  (131)  recovered 
spontaneously.
Figure 5.7 Supportive treatment
Table-5.8 Complications
Complications Cases
No. Percentage
Acute renal failure 38 23.8
Respiratory failure 15 9.1
Cellulitis or necrosis that needed 
debridement
3 1.8
Total  complications 56 34.1
No complications 108 65.9
Total 164 100
         As seen in the table-5.8 in our study, 65.9% of the patients (108) recovered 
well without any complications. In the remaining 34.1% of the patients (56), 
23.8% of the patients (38) developed acute renal failure, 9.1% of the patients 
(15)  developed  respiratory  failure  and  1.8%  of  the  patients  (3)  developed 
cellulitis or necrosis that needed debridement.
Figure 5.8 Complications
Table-5.9 Bite to needle time
Bite to needle time Cases
No. Percentage
0-4 hrs 66 40.2
4-8 hrs 63 38.4
8-12 hrs 16 9.8
12-24 hrs 15 9.1
More than 24 hrs 4 2.4
Total 164 100
Range 1-58 hrs
Mean 7.03 hrs
SD 8.03 hrs
       The bite to needle time (time between snake bite and administration of 
ASV) varied between 1 and 58 hours in our study. The bite to needle time was 
0-4 hours in 40.2% of the patients (66); 4-8 hours in 38.4% of the patients (63); 
8-12 hours in 9.8% of the patients; 12-24 hours in 9.1% of the patients (15) and 
more than 24 hours in 2.4% patients (4). The mean bite to needle time was 7.03 
hours. The standard deviation was 8.03 hours. 
Figure 5.9 Bite to Needle time
Table-5.10 Bite to needle time and complications
Bite  to 
needle time
Complications
Acute renal 
failure
Respiratory 
failure
Cellulitis or 
necrosis that 
needed 
debridement
Total
No. Percent No. Percent No. Percent No. Percent
0-4 hrs 8 12.1 2 3.0 2 3.0 12 18.2
4-8 hrs 14 22.2 8 12.7 - - 22 34.9
8-12 hrs 6 37.5 1 6.3 1 6.3 8 50
12-24 hrs 6 40 4 26.7 - - 10 66.7
>24hrs 4 100 - - - - 4 100
Mean  bite 
to  needle 
time
12.4 8.2 6.1 10.9
            The table-5.10 showed the occurrence of various complications in the 
relation to the bite to needle time. In the group with bite to needle time of 0-4 
hours, 12.1% of the patients (8) had acute renal failure, 3% of the patients (2) 
had respiratory  failure  and 3% of  the  patients  (2)  had cellulitis  that  needed 
debridement. 
Figure 5.10 Bite to needle time and complications
              In the group with bite to needle time of 4-8 hours, 22.2% of the patients 
(14) had acute renal failure and 12.7% of the patients (8) had respiratory failure. 
Among the group with bite to needle time of 8-12 hours, 37.5% of the patients 
(6) had acute renal failure, 6.3% of the patients (one) had respiratory failure and 
6.3% of the patients (one) had cellulitis that needed debridement. In the age 
group with bite to needle time of 12-24 hours, 40% of the patients had acute 
renal failure and 26.7% of the patients had respiratory failure. In the group with 
bite to needle time of more than 24 hours, all patients (100%) had acute renal 
failure.
Table-5.11 Correlation between bite to needle time and complications 
Bite to needle time Complications No complications
Total
No. Percentage No. Percentage
0-4 hrs 12 18.2 54 81.8
4-8 hrs 22 34.9 41 65.1
8-12 hrs 8 50 8 50
12-24 hrs 10 66.7 5 33.3
>24hrs 4 100 - -
Mean  bite  to  needle 
time
10.9 5.0
SD 12.1 3.4
‘p’ value 0.0001 (significant)
Figure 5.11 Correlation between bite to needle time and complications
              In our study the bite to needle time was well correlated with the  
complications as shown in the table-5.11. In this study among the group with 
bite  to  needle  time  of  0-4  hours,  81.8%  of  the  patients  (54)  had  no 
complications and 18.2% of the patients (12) had complications. 
              In the group with bite to needle time of 4-8 hours, 65.1% of the patients 
(41) had no complications and 34.9% of the patients (22) had complications. 
Among  the  group  with  bite  to  needle  time  of  8-12  hours,  50%  (8)  had 
complications  and 50% (8)  had no complications.  In  the group with bite  to 
needle time of 12-24 hours, 66.7% of the patients (10) had complications and 
33.3% of the patients (5) had no complications. In the group with bite to needle 
time of more than 24 hours, 100% of the patients (4) had complications. 
            The mean bite to needle time was 10.9 hours in the group with 
complications  and  5  hours  in  the  group  without  complications.  This  is 
statistically significant (‘p’ value -0.0001).
6. DISCUSSION
           All the patients with history of snake bite were considered for the study 
and 164 patients  were  selected  for  our  study.  These  patients  had undergone 
various investigations like clotting time (20WBCT),  blood sugar, urea, serum 
creatinine, urine for albumin, sugar and deposits, complete blood count, liver 
function tests and ultra sonogram (for selected patients). ASV was administered 
for those patients indicated. The indications were
Systemic envenomation:
a) Haemostatic abnormalities: spontaneous systemic bleeding, coagulopathy 
(20WBCT) or thrombocytopenia
b) Neurotoxic signs: ptosis, external ophthalmoplegia, paralysis etc 
c) Cardiovascular  abnormalities:  hypotension,  shock,  cardiac  arrhythmia 
and abnormal ECG
d) Acute renal failure: oliguria/anuria  and rising blood creatinine/ urea 
e) Haemoglobinuria/myoglobinuria: dark brown urine, urine dipsticks, other 
evidence of intravascular haemolysis or generalised rhabdomyolysis 
f) Supporting laboratory evidence of systemic envenomation 
Local envenomation:
a) Local  swelling  involving  more  than  half  of  the  bitten  limb  (in  the 
absence of a tourniquet) and swelling after bites on the digits (toes and 
especially fingers)
b) Rapid extension of swelling (for example beyond the wrist or ankle 
within a few hours of bites on the hands or feet)
c) Development  of  an  enlarged  tender  lymph node draining the  bitten 
limb
          The presence of any adverse reactions were noted and treated accordingly. 
Clotting  time  was  repeated  every  6  hours  for  those  who  presented  with 
hemotoxicity and treated with ASV as indicated in the review of literature. The 
complications  due  to  the  snake  bite  due  to  the  late  arrival  and  late 
administration of ASV were noted. The bite to needle time which is the time 
between the time of snake bite and time of ASV administration were noted and 
the parameters were analyzed.
            In our study, 164 patients were selected for study. In these patients,  
63.4% of the patients (104) were males and 36.6% of the patients were females. 
One study which was conducted by Narvencar K., J Assoc Physicians India.,  
2006 Sep;54:717-9 showed that 90% of the patients were males as compared to 
10% of females among 50 patients of his study.  Hansdac SG et al had found 
that snake bites were 2.5 times more common in males. Meyer WP et al found 
85% of patients to be males. 
              The high incidence of snake bites in males is probably due to their  
lifestyles  and  occupational  exposures  as  farmers  or  herdsmen,  while  most 
females in our state are usually housewives or office workers, thus less prone 
for snake bites.
              In our study as seen in table-5.1, the incidence of snake bite occurred 
commonly in the age group of 20-50 years. 16.7% of cases seen in the ages of 
above 50 years. In the study by Narvencar K., J Assoc Physicians India., 2006 
Sep;54:717-9  showed that the maximum number of cases (66%) were in the 
age group of 11-40 years, while only 8% were above the age of 60 years. This 
was similar to the observation of Thomas G Glass who found 74% incidence in 
the age of 10-70 years while only 2% were above 70 years The high incidence 
in the age group of 11-40 years is again because of occupational exposure, this 
being the productive age group.
               Among the study population, as seen in the table-5.3, 75.6% of the  
snake bites occured in their working fields and 24.4% of the snake bites occured 
in their houses. The high number of snake bites in the fields is related to the 
working place, agricultural land, the prey base of the snake (that is frogs 
and rats).The rice fields, which harbour millions of rats attract a lot of 
snakes. Humans go into the field every morning and come out in the 
evening, just the time when snakes are active. Thus, the chance of an 
encounter between farmer and snake is very high. As more areas are 
inhabited at the periphery of towns, even there the chances of human / 
snake interaction increase.
         In this study, 41.6% of snake bites occurred in right lower limb, 35.9% of 
the bites occurred in left lower limb, 13.4% of the bites occurred in left upper 
limb and 8.5% of the bites occurred in right upper limb. The manual working 
nature of our people is responsible for  the increased number of  bites  in the 
lower limbs.
            In our study, 90.9% of the patients presented to the hospital with the 
local  manifestations  of  the  envenomation  which  includes  local  cellulitis, 
regional  lymphadenitis,  local  bruises  and  hematological  abnormalities  like 
prolonged clotting time, acute renal failure and coagulopathy and 9.1% of the 
patients  presented  with  neurotoxic  manifestations.  67.7%  of  the  patients 
presented with prolonged clotting time and 32.3% of the patients presented with 
normal clotting time.
            The complications due to late administration because of late arrival of 
the  patients  were  noted.  The  complications  noted  were  acute  renal  failure 
(serum  creatinine  >1.5  mg/dl  or  oliguria  <400ml/day);  disseminated 
intravascular  coagulation  or  primary  fibrinolysis;  compartment  syndrome, 
gangrene,  cellulitis/necrosis  that  needed  debridement;  shock;  sepsis;  acute 
respiratory  distress  syndrome;  neurological  paralysis  requiring  ventilatory 
support.   
             As seen in the table-5.8 in our study, 65.9% of the patients recovered 
well without any complications. In the remaining 34.1% of the patients (56), 
23.8% of the patients (38) developed acute renal failure, 9.1% of the patients 
(15)  developed  respiratory  failure  and  1.8%  of  the  patients  (3)  developed 
cellulitis or necrosis that needed debridement. In the study by Narvencar K., J 
Assoc Physicians India., 2006 Sep;54:717-9, among the 50 patients, 30 cases 
recovered  well  without  any  complications  and  20  cases  resulted  in 
complications.
           The bite to needle time varied between 1 and 58 hours in our study. The  
bite to needle time was 0-4 hours in 40.2% of the patients (66); 4-8 hours in 
38.4% of the patients (63); 8-12 hours in 9.8% of the patients; 12-24 hours in 
9.1% of  the  patients  (15)  and more  than 24  hours  in  2.4% patients  (4).  In 
Narvencar K., J Assoc Physicians India., 2006 Sep;54:717-9 study among the 
50 patients, 36 patients came to the hospital within 6 hours; seven patients in 6-
24 hours; five patients  in 1-3 days and two patients came to the hospital after 3 
days. 
           The late arrival of the patients are due to poor knowledge about the snake 
bite, their belief in the traditional methods such as application of tourniquet, 
cutting (incision) and suction, washing the wound, snake stone or other methods 
which are useless and harmful and delay in transporting the patients from the 
periphery.
              In our study among the group with bite to needle time of 0-4 hours,  
81.8% of the patients (54) had no complications and 18.2% of the patients (12) 
had complications. In the group with bite to needle time of 4-8 hours, 65.1% of 
the  patients  (41)  had  no  complications  and  34.9% of  the  patients  (22)  had 
complications. Among the group with bite to needle time of 8-12 hours, 50% (8) 
had complications and 50% (8) had no complications. In the group with bite to 
needle time of 12-24 hours, 66.7% of the patients (10) had complications and 
33.3% of the patients (5) had no complications. In the group with bite to needle 
time of more than 24 hours, all patients (4) had complications. Chi-square test 
was used to find the significance and that is found to be statistically significant 
(‘p’ value -0.0001) in this study.
       The study by Narvencar K., J Assoc Physicians India., 2006 Sep;54:717 
showed that  the  incidence  of  complications  was directly  proportional  to  the 
timing  of  ASV  administration.  The  late  administration  resulted  in  more 
complications.  In his study, the complications were less in the population who 
presented to the hospital as early as within 6 hours (26 cases were complicated 
and 10 cases were uncomplicated). Among the seven patients with bite to needle 
time of 6-24 hours four cases were complicated and three were uncomplicated. 
In the group with bite to needle time of 1-3 days, 80% of the patients (4) got 
complications  and  20% (one)  recovered  without  any  complications.  All  the 
patients who presented late with bite to needle time of more than 3 days had for 
complications (100%).
       This  finding is  similar  to  the observation made by  Vijeth SR  et  al., 
JIPMER  that the incidence of complications was directly proportional to the 
duration of venom in the blood prior to neutralization by ASV. This fact is also 
proved  by  Ash  T  et  al and Thomas  L  et  al who  documented  a  positive 
correlation between severity of renal failure and increased time interval between 
bite and ASV administration.
         One  study by  K. Sam and M. Khan et al., The Internet Journal  
of Emergency Medicine., 2009 Vol. 5  showed that snake bite severity 
scores were directly proportional to the time elapsed between snake bite 
instance and hospitalisation time. Those patients who were admitted late 
had higher number of complications like renal failure (52%), breathing 
difficulty (42%), cellulitis (40%), abnormal PT and APTT in 42% and 39% 
of cases respectively. Mortality rate was the highest (16%) and higher 
morbidity and squeal were observed among patients (18%) who were 
admitted  after  24  hours  of  envenomation.  Majority  (64%)  of  those 
admitted after 13-18 hours seemed to have moderate severity with life 
threatening symptoms, while those patients (82%), who were admitted 
within six hours improved. 
            The fact that the incidence of complications was directly proportional to  
the duration of venom in the blood prior to its neutralization by ASV due to late 
arrival of the patient at hospital, point to the possibility or direct toxicity of the 
venom on organ systems of the body. Based on the findings of present study, we 
suggest  that  the  early  institution  of  ASV  is  beneficial  in  preventing 
complications however severe the systemic envenomation. The delay in ASV 
administration could increase the incidence of complications and morbidity as 
observed from the present study. 
7. CONCLUSION
 The incidence of complications is directly proportional to the duration of 
venom in the blood prior to neutralization by ASV due to late arrival of 
patient at hospital. 
 The early institution of  ASV is  beneficial  in  preventing complications 
however severe is the systemic envenomation.
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Correlation between timing of ASV administration and complications of snake 
bite
Patient’s Name:                                                                                Age:                       Sex:
IP No :                                                                                                 Address:
DOA:                                            DOD:
Presentation:
History of Snake bite on- Date:                               Time:                       Site: 
Clothing: +/-                                                           Time of reaching hospital: 
On examination,                                           
Cellulitis/   Regional  lymphadenitis/   Ptosis/    Diplopia/   Dysphagia/    Dysphonia/ 
Muscle paralysis/   Weakness/     Respiratory distress/     Confusion
PR:                          BP:                                          RR:                                   CVS: 
RS:                                                  Abdomen:                                              CNS:
Investigations:
CT:           
                                                                                                                              
Blood sugar:  Urine 
albumin: 
Blood urea  : Urine sugar:
Serum creatinine: Urine deposits:
Complete blood count:  TC:                               DC:                                                     Hb: 
LFT: 
Others:
Treatment  given:
ASV:                  vials. (started at                                        )
Total doses of ASV:   
Antibiotics: 
Others:    Fasciotomy/   Dialysis/   Ventilatory support/  Blood transfusion
Complications:
Acute renal failure/  Shock/  Sepsis/  ARDS/  Respiratory failure requiring ventilator support/ 
DIC/  
Compartmental syndrome, gangrene, cellulitis or necrosis that needed  debridment
PROFORMA
Time of snake bite  :
Time of ASV  given :
Bite to needle time:                                      
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1 62750 55 M RAN F L 18 min 90 25 1.2 10 10 AB Nil Nil 3
2 63559 34 F LEL H L >20 min 264 23 0.8 5 5 AB Nil Nil 16.3
3 63579 18 F RFH H L 15 min 101 19 0.8 5 5 AB Nil Nil 12
4 63480 38 F LFR F L >20 min 69 17 0.7 8 15 AB Nil Nil 2.3
5 63088 45 F LFR H N 13 min 367 24 0.9 10 10 AB Vent RF 4.3
6 63526 36 M RAN F L >20 min 144 46 1.8 8 15 AB Nil ARF 4.2
7 64050 55 M RFT F L >20 min 298 92 3.4 10 15 AB Nil ARF 2.3
8 65593 29 F RFR F L >20 min 192 23 1 10 15 AB Nil Nil 9
9 65809 25 M RFT F L 7 min 86 36 1.3 8 8 AB Nil Nil 2.5
10 66677 35 M RFR H N 12 min 83 25 0.8 5 15 AB Vent RF 5.15
11 66678 47 M RFT F L >20 min 85 40 1.1 15 20 AB
Bloo
d Nil 4.25
12 66296 14 M RFT F L >20 min 60 110 3.8 10 15 AB Dial ARF 58
13 67786 22 M LFT H L 4 min 114 18 1 8 8 AB Nil Nil 7.45
14 67529 60 F LFT F L >20 min 118 77 2 10 10 AB Nil ARF 10
15 68338 45 M RHA H L >20 min 101 24 0.9 5 5 AB Nil Nil 3.3
16 69317 30 M RFT F L >20 min 82 29 1 5 5 AB Nil Nil 1
17 69093 40 M LFT F L >20 min 104 28 1 5 5 AB Nil Nil 7.3
18 68024 29 F RFT H L 7 min 71 18 0.6 5 10 AB Nil Nil 7.15
19 68659 29 F LFR F N 6 min 84 21 0.8 15 15 AB Nil Nil 4.3
20 68776 13 M RFT H L >20 min 130 28 0.9 8 8 AB Nil Nil 4.45
21 69545 37 F RTO H N 7 min 92 18 0.6 10 18 AB Nil Nil 5.15
22 69343 45 F RFT H N 12 min 60 37 0.9 10 10 AB Vent RF 5.3
23 69924 42 F RFA F N 5 min 234 27 1 15 15 AB Vent RF 12.3
24 69938 47 M RFT F N 12 min 130 28 0.7 15 15 AB Nil RF 7.15
25 70298 30 F LTO H L 12 min 164 18 0.7 5 5 AB Nil RF 16.45
26 70219 70 F RHA F L 8 min 102 20 1 5 5 AB Nil Nil 3
27 71348 50 F LFR H L >20 min 63 18 0.7 10 15 AB Nil Nil 2.3
28 70269 38 M RFT F L >20 min 291 30 1.2 10 10 AB Nil Nil 2.45
29 71314 30 M RHA F L 13 min 63 20 0.6 13 13 AB Nil Nil 2.3
30 71844 58 F RFT F L >20 min 65 61 2.2 15 15 AB Nil ARF 7.45
31 71827 45 M RLE H L 9 min 66 30 0.9 8 8 AB Nil ARF 19.3
32 71834 26 M RFT F N 8 min 124 29 0.9 15 15 AB Nil Nil 6.15
33 73077 60 M LLE H L >20 min 65 30 0.7 10 15 AB Nil Nil 9
34 73088 28 M RFT H L >20 min 89 25 0.8 5 5 AB Nil Nil 7.3
35 73060 17 M LLE H L >20 min 65 18 0.7 5 10 AB Nil Nil 2
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36 73469 45 F LFT H L >20 min 93 41 1 10 18
A
B Nil ARF 20.45
37 73537 52 F RLE F L >20 min 80 24 0.8 5 15
A
B Nil Nil 3.45
38 73334 22 M RFT F L 10 min 95 21 0.8 8 8
A
B Nil Nil 2
39 73531 18 M LFR F L 5 min 145 33 0.8 5 5
A
B Nil Nil 5
40 73570 40 M LFT H L >20 min 122 33 1.1 10 20
A
B Nil Nil 3
41 73571 35 M LEL F L >20 min 147 30 1.1 10 20
A
B Nil Nil 3
42 73546 15 M LLE F L 5 min 86 24 0.7 5 10
A
B Nil Nil 5
43 73624 35 F RTO F L >20 min 60 23 0.7 10 10
A
B Nil Nil 4
44 74381 68 M RLE F L >20 min 224 64 1.7 10 10
A
B Nil ARF 8.3
45 74023 65 M RFT F L >20 min 166 87 2.5 10 10
A
B Nil ARF 10.3
46 74087 60 F LFT H L >20 min 105 35 0.9 10 10
A
B Nil Nil 4.3
47 74792 40 F RFT H L 8 min 368 42 1.8 5 15
A
B Nil ARF 41
48 74647 21 M LLE H L >20 min 147 62 2.3 8 18
A
B Nil ARF 3
49 74684 57 M RSH H L >20 min 120 30 1.2 8 15
A
B Nil Nil 1.1
50 74634 37 M RFT F L >20 min 107 18 0.9 8 13
A
B Nil Nil 3
51 72576 45 M RLE H L 14 min 148 69 2.5 3 3
A
B Dial ARF 57
52 75274 40 F RLE F L >20 min 209 19 0.8 10 15
A
B Nil Nil 4
53 75163 17 M RLE F L >20 min 64 27 0.9 10 15
A
B Nil Nil 3
54 75064 50 M LFR F L >20 min 70 69 1.9 8 8
A
B Nil Nil 8.1
55 75229 14 M LFT F L >20 min 140 27 1.2 8 8
A
B Nil Nil 4
56 75391 30 F RLE H L 10 min 94 23 0.8 10 15
A
B Nil Nil 4.25
57 75916 37 M RFR F L >20 min 64 23 0.9 10 10 A Nil Nil 4.15
B58 75139 40 F LLE F L >20 min 114 26 0.8 10 25
A
B Nil Nil 9.1
59 78484 40 M RLE H L >20 min 109 22 1 10 10
A
B Nil Nil 3
60 79029 32 F RAN F N 11 min 113 25 0.9 20 28
A
B Vent RF 14.3
61 78726 45 M RTH F L 9 min 75 18 0.9 5 5
A
B Nil Nil 3.3
62 78682 51 M RFT F L >20 min 145 22 0.8 5 5
A
B Nil Nil 6
63 78759 13 M RFT F L >20 min 96 70 1 5 5
A
B Nil RF 5
64 78758 45 M RLE F L >20 min 92 18 0.7 5 5
A
B Nil Nil 6.1
65 79007 56 M RFT F L >20 min 130 38 1 13 13
A
B Nil Nil 3.45
66 76275 18 F RLE F L 10 min 69 28 0.9 15 15
A
B Nil Nil 5
67 79292 21 F LFT F L 7 min 65 28 0.9 5 5
A
B Nil ARF 15.15
68 79457 30 F RFT F L >20 min 115 23 0.8 10 10
A
B Nil Nil 3
69 79826 19 F LFT F L >20 min 91 25 0.8 15 15
A
B Nil Nil 6
70 79806 22 F LFT F L 10 min 64 18 0.8 10 10
A
B Nil Nil 5
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71 80429 52 M LFT F L >20 min 93 24 0.9 8 8 AB Nil Nil 3
72 80199 32 M RFT F L 10 min 70 19 0.8 8 8 AB Nil Nil 3.15
73 79336 65 M LFT F L >20 min 120 32 0.9 15 25 AB Nil Nil 2.3
74 79316 18 M LFT F L 10 min 60 42 1 10 20 AB Nil ARF 7.4
75 80172 40 M RFR H N 10 min 112 40 0.7 10 10 AB Vent RF 8
76 79838 45 M RLE F L 12 min 110 48 1.6 10 10 AB Nil ARF 6.3
77 79815 35 M LHA F L >20 min 73 22 0.9 10 10 AB Nil Nil 4.45
78 80173 24 M RFT H L >20 min 70 43 2 8 13 AB Nil ARF 7
79 80124 55 M LTO F L >20 min 111 53 1.2 10 10 AB Nil Nil 8
80 80637 40 M LFR F L 9 min 74 62 0.8 10 10 AB Nil Nil 6.45
81 81119 50 F LLE H L >20 min 86 31 1 15 17 AB Nil Nil 3.3
82 80683 65 M LLE F L 7 min 68 30 0.9 5 5 AB Nil Nil 20.3
83 80600 36 M LFT F L >20 min 60 32 1.7 5 10 AB Nil Nil 6.3
84 80430 60 F LAN H L >20 min 84 18 0.8 8 18 AB Nil Nil 3.55
85 81076 49 M RAN F L 8 min 65 25 0.9 7 11 AB Nil ARF 4.3
86 81732 46 M LFT F L >20 min 88 30 0.9 5 5 AB Nil Nil 14.3
87 82114 40 F LFR F L 8 min 108 23 1 10 10 AB Nil Nil 7
88 82374 13 F LFR F L >20 min 84 14 0.8 10 20 AB Nil Nil 5
89 82490 45 F LFT H L >20 min 91 37 1 10 10 AB Nil Nil 4
90 82547 55 M LFT F L >20 min 88 18 0.8 5 5 AB Nil Nil 1.45
91 82544 30 M LTO F L >20 min 76 18 0.7 5 5 AB Nil Nil 10
92 82022 35 M RFT F L 8 min 82 17 0.7 5 5 AB Nil Nil 5
93 82287 22 M RFT F L >20 min 90 79 3 15 15 AB Nil Nil 8
94 82254 14 M LFT F L >20 min 192 20 0.8 15 15 AB Nil Nil 2
95 82274 37 F LFT H L >20 min 70 30 1.5 15 15 AB Nil Nil 4
96 81460 50 M RFR H N 10 min 70 18 0.8 15 25 AB Vent RF 6.5
97 81409 23 M RFT H L >20 min 123 71 3.1 10 10 AB Dial ARF 4
98 81949 30 M RTH F L >20 min 254 34 1.8 10 10 AB Dial Nil 3.3
99 81989 37 F LFT H L >20 min 71 39 1.5 15 15 AB Nil ARF 6.3
10
0 82680 20 M LLE F L >20 min 94 21 0.9 5 5 AB Nil Nil 7
10
1 82261 24 F LFT F L >20 min 62 16 0.8 8 8 AB Nil ARF 7
10
2 82165 40 F RFR F L >20 min 91 30 0.7 10 18 AB Nil Nil 6
10
3 84528 28 M LTO F L 5 min 62 43 0.9 5 5 AB Nil Nil 5.05
10
4 84594 42 F LLE F L >20 min 183 23 0.9 5 10 AB Nil Nil 10.5
10
5 83243 24 F LHA F L >20 min 62 18 0.8 5 10 AB Nil Nil 2.3
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10
6 83232 43 F LFT F L >20 min 180 16 0.7 15 30 AB Vent RF 3.3
10
7 83031 16 M RTO F L 10 min 115 22 0.7 8 8 AB Nil Nil 3.15
10
8 83291 55 M RFT F L >20 min 73 19 0.8 10 15 AB Nil Nil 13.3
10 83056 15 M LLE F L >20 min 133 23 0.8 10 10 AB Nil Nil 5
9
110 83031 45 F RLE H N 8 min 188 44 1.1 18 18 AB Nil Nil 2.15
111 84387 35 M LLE H L 11 min 78 36 1 10 12 AB Nil Nil 3.3
112 84323 13 F LFT F L 10 min 91 39 1.2 8 8 AB Nil Nil 6.3
113 84472 40 M LFT F L >20 min 144 36 1 10 10 AB Nil RF 16
114 84620 23 M LLE F L >20 min 82 32 1.1 10 20 AB Nil Nil 4
115 84320 44 F RFT F L >20 min 108 60 2.2 10 15 AB Nil ARF 3.3
116 84945 29 M RFT F L >20 min 106 39 2.5 18 23 AB Blood ARF 9
117 85704 50 M LEL F N 6 min 160 28 0.9 10 40 AB Vent RF 9.3
118 85852 54 M LFT F L >20 min 71 68 1.9 10 10 AB Nil Nil 4.5
119 85901 45 M RFT F L >20 min 124 43 1.5 10 20 AB Blood ARF 2.4
12
0 87377 27 M LTO F L >20 min 168 22 0.8 15 25 AB Nil Nil 3.3
12
1 86718 46 M RFT F L >20 min 108 24 0.8 10 15 AB Nil Nil 6.3
12
2 86920 44 M LHA F L >20 min 89 90 5.9 15 15 AB Dial ARF 5
12
3 87336 33 M RFT F L 10 min 82 18 0.9 5 5 AB Nil Nil 2
12
4 86818 25 F LHE F L 12 min 89 30 0.7 5 10 AB Nil Nil 6
12
5 90307 15 M LLE F L >20 min 78 30 1 10 10 AB Nil Nil 3.1
12
6 89347 60 F RAN F L >20 min 84 20 0.9 20 30 AB Nil Nil 4.3
12
7 89237 35 M RHA F L >20 min 101 20 0.8 10 25 AB Nil Nil 16.45
12
8 90578 45 M RFT F L >20 min 76 26 0.8 10 18 AB Nil Nil 4.3
12
9 90612 29 M LLE F L >20 min 115 16 0.6 5 10 AB Nil Nil 3.15
13
0 89110 23 M LFT F L >20 min 74 56 2.5 10 10 AB Dial ARF 3
13
1 87602 25 F LAN F L >20 min 100 28 0.9 5 5 AB Nil Nil 3
13
2 87672 20 M LFT F L >20 min 108 22 0.8 5 5 AB Nil Nil 4.15
13
3 87961 37 F RTO F L 10 min 80 24 0.8 5 5 AB Nil Nil 7.45
13
4 88355 24 F LLE H N 15 min 140 28 0.9 10 10 AB Vent RF 3
13
5 35090 29 M LLE F L >20 min 157 20 0.8 15 20 AB Nil Nil 5.3
13
6 36673 60 F LLE F L >20 min 72 42 1 10 10 AB
Fasci
o C/N 3
13
7 36096 25 M LFT F L >20 min 139 50 1.9 15 20 AB
Fasci
o ARF 3.3
13
8 23252 50 M LLE F L >20 min 148 28 1 10 25 AB
Fasci
o C/N 3.3
13
9 100189 55 F LLE F L 10 min 105 204 4.3 15 15 AB Dial ARF 43
14
0 99079 49 F LFR F L >20 min 98 135 3.3 5 10 AB Nil ARF 13
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14
1 92113 37 F LEL F L >20 min 116 125 1.5 10 13 AB Dial ARF 19.3
14
2 93398 56 F RFT F L >20 min 102 26 0.9 10 20 AB Blood Nil 10.3
14
3 91987 15 M LFR H N 14 min 129 18 0.8 15 30 AB Vent RF 6.3
14
4 92113 37 F LAR H L >20 min 92 45 2.2 10 13 AB Dial ARF 19.3
14
5 93220 42 F LHA F L 15 min 114 64 3 5 20 AB Nil ARF 11
14
6 91383 30 M RFT F L >20 min 66 19 0.8 10 15 AB Nil Nil 3.3
14
7 90429 70 F RLE F L >20 min 105 96 2.6 20 20 AB Dial ARF 4.45
14
8 40221 15 M RFT H L 4 min 119 19 0.9 10 13 AB Nil Nil 3
14
9 40702 50 M LFT F L >20 min 132 39 1.2 10 20 AB Nil Nil 2
15
0 40718 22 M LFT F L >20 min 68 30 0.9 10 10 AB Nil Nil 2
15
1 40637 18 M RTO F L >20 min 101 20 1 10 10 AB Nil Nil 2
15
2 54827 45 M LFT F L 12 min 103 60 1.3 10 10 AB Fascio C/N 12
15
3 56750 40 M LFT F L >20 min 96 102 3.2 20 25 AB Nil ARF 2.15
15
4 72688 18 M LHA F L >20 min 90 75 2.7 10 18 AB Nil Nil 2.3
15
5 72809 20 M RFT F L 12 min 99 33 1.5 8 8 AB Nil Nil 5.15
15
6 72551 35 M RFR F L 8 min 61 37 1.4 8 8 AB Nil Nil 1.4
15
7 82707 33 M RFR F L >20 min 62 40 1.3 10 15 AB Nil Nil 2.15
15
8 82547 40 M LFT F L 5 min 92 34 1 10 15 AB Nil Nil 3
15
9 81813 60 F RLE F L 8 min 108 52 1.8 8 8 AB Dial ARF 4.15
16
0 81549 47 M RLE F L >20 min 67 37 1.7 10 15 AB Dial ARF 10
16
1 82670 25 F RAN F L >20 min 132 104 4.3 10 15 AB Nil ARF 6
16
2 77488 27 F RLE F L >20 min 98 54 1.9 15 15 AB Dial ARF 8
16
3 82956 24 M RTO F L >20 min 68 22 0.8 10 10 AB Nil Nil 3
16
4 75220 35 M RFT F L >20 min 74 106 5 15 25 AB Dial ARF 5.3
KEY TO MASTER CHART
M- Male                                                           R/LLE- Right/Left leg
F- Female                                                         R/LTH- Right/Left thigh
H- House                                                          R/LFT- Right/Left foot
L-Local (Cellulitis/coagulopathy)                    R/LAN- Right/Left ankle
N- Neurological                                                R/LTO- Right/Left toe
AB-Antibiotics                                                  R/LFR- Right/Left finger
Dial- Dialysis                                                    R/LEL- Right/Left elbow
Fascio- Fasciotomy                                           R/LSH- Right/Left Shoulder
Vent- Ventilatory support                                 R/LHA- Right/Left hand
ARF- Acute Renal Failure                                R/LFA- Right/Left forearm
RF- Respiratory failure
C/N- Cellulitis /necrosis that needed debridement
